| Biomarker ID | 1159 |
| PMID | 23826311 |
| Year | 2013 |
| Biomarker | Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993] |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Localised Vs Advanced Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 70 PCa samples into a training set with 37 PCa samples (21 post-surgery Gleason score ,7, 16 post-surgery Gleason score .7). The remaining 33 samples with post-surgery Gleason score 7 were used as a test set. |
| Senstivity | Test Set: 80% (95% CI 29%– 97%) |
| Specificity | Test Set: 82% (95% CI: 63%–94%) |
| AUC | Training: 0.99 (95% CI: 0.87–1.00); Testing: [0.83 (95% CI 0.66–0.94)] |
| Accuracy | NA |
| Level Of Significance | p=0.0055 |
| Method Used | capillary electrophoresis mass spectrometry |
| Clinical | No |
| Remarks | EAU classification was used as reference standard |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |